Efficacy of Acupuncture for Primary Insomnia: A Randomized Controlled Clinical Trial
Table 2
Change in SF-36 (Mean ± SD) from baseline to 2-month follow-up.
Item timepoint
Verum group
Estazolam group
Sham group
Verum versus sham
Verum versus estazolam
Estazolam versus sham
PF
Baseline
Week 6
0.68
0.35
0.18
2-month follow-up
0.05
0.24
0.42
RP
Baseline
Week 6
0.18
0.63
0.07
2-month follow-up
0.15
0.31
0.66
BP
Baseline
Week 6
0.85
0.24
0.18
2-month follow-up
0.30
0.63
0.13
GH
Baseline
Week 6
0.11
0.31
0.53
2-month follow-up
0.11
0.21
0.69
VT
Baseline
Week 6
0.002
<0.001
0.01
2-month follow-up
0.001
<0.001
0.10
SF
Baseline
Week 6
0.02
0.75
0.03
2-month follow-up
0.24
0.56
0.08
RE
Baseline
Week 6
0.29
0.16
0.02
2-month follow-up
0.04
0.21
0.42
MH
Baseline
Week 6
0.32
0.56
0.12
2-month follow-up
0.14
0.70
0.27
SF-36: 36-item short-form health survey; MH: mental health; PF: physical functioning; RP: role-physical; BP: bodily pain; VT: vitality; GH: general health; SF: social functioning; RE: role-emotional. Data from multivariate analysis of variance (MANOVA) and repeated measures. (Mauchly’s test of sphericity: .) *Comparison within each group with baseline .